Navigation Links
Palomar Wins Two European Hair Removal Patent Opposition Hearings
Date:5/14/2009

BURLINGTON, Mass., May 14 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, announced today that Palomar won two patent opposition cases held at the European Patent Office on May 6 and 13, 2009. The opposition hearings concerned European Patents Nos. 1 230 900 and 0 806 913, respectively, which correspond to U.S. Patent Nos. 5,595,568 and 5,735,844. This light-based hair removal patent family has already been licensed to ten competitors and is the subject of patent infringement lawsuits against Candela and Syneron in the United States.

A panel of three patent examiners from the European Patent Office upheld the patents as both novel and inventive over prior art raised by competitors.

Patricia Davis, Palomar's General Counsel and a registered patent attorney, commented, "These findings by the European Patent Office support the strength of these European patents as well as emphasize the importance of the entire patent family. The prior art raised by the opponents in Europe includes some of the same prior art being relied upon by Candela Corporation in their re-examination request before the U.S. Patent Office and in their defense to our patent infringement lawsuit in the U.S. District Court District of Massachusetts. We are confident that the U.S. Patent Office will find U.S. Patent Nos. 5,595,568 and 5,735,844 valid and that we will be successful in our patent infringement lawsuits against both Candela and Syneron, Inc."

Ms. Davis continued, "Palomar has received over $80 million in royalties from licensees to this light-based hair removal patent family. Importantly, in the last month, we signed patent license agreements with two new licensees, to bring the current number of licensees to ten."

Chief Executive Officer Joseph P. Caruso commented, "We are very pleased with the ruling by the European Patent Office. We have always believed in the strength of this patent family, and we will continue to aggressively enforce our portfolio of patents in a number of key areas."

If Palomar prevails at trial, Candela and Syneron may be ordered to pay tens of millions in damages for past sales and ordered to stop selling infringing products. Palomar also alleges that Candela's and Syneron's activities constitute willful infringement of U.S. Patent Nos. 5,595,568 and 5,735,844. If Palomar prevails on such claims, Candela and Syneron could be forced to pay up to triple the amount of the original damages assessment and Palomar's legal fees.

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current expectations, plans, intentions, beliefs or predictions. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2008 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    Contacts:  Kayla Castle
               Investor Relations Manager
               Palomar Medical Technologies, Inc.
               781-993-2411
               kcastle@palomarmedical.com


'/>"/>
SOURCE Palomar Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Palomar Medical Technologies Third Quarter 2007 Financial Results Conference Call and Webcast
2. Palomar and Gillette Extend Launch Decision on Home-Use Light Based Hair Removal Device and Agree to Negotiate New Terms
3. Palomar to Debut New Technology at the American Academy of Dermatology Annual Meeting
4. Palomar Seeks to License Additional Companies to Home-Use Light-Based Hair Removal Technology
5. Palomar to Unveil New Laser-Assisted Liposuction Platform at the American Society for Laser Medicine & Surgery
6. Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008
7. Palomar Medical Reports Financial Results for Third Quarter 2008
8. Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensing Program
9. Reliant Technologies, and Palomar Medical Technologies, Announce Launch of a Fractional Technology Licensing Program
10. Palomar Medical Technologies to Host Fourth Quarter and Year End 2008 Financial Results Conference Call and Webcast on February 5, 2009
11. Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Utah (PRWEB) , ... January 17, 2017 , ... ... of accredited, online continuing education for EMS and firefighting professionals, has released four ... (VILT) Solution. These new courses are taught live in an online classroom and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... today announced its partnership with Sigfox in the U.S.A. to offer ... nationwide including new offerings on large-scale environmental sensor deployments such as monitoring ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/16/2017)... ... 17, 2017 , ... To provide comfort and fuel during ... fast-casual category, announces a hearty and wholesome Winter Menu. Starting today, guests can ... Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken & Sausage Soup, ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  Market Research Future published a ... Devices Market is expected to reach USD 33.6 million during the ... Market Highlights ... The Global Endoscopy Devices Market has been examined as a swiftly ... there is huge demand for endoscopy device in various regions.  The ...
(Date:1/17/2017)... YORK , Jan. 17, 2016  Attorney Advertising -- ... behalf of purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the ... to obtain additional information and assist the investigation by visiting ... concerns whether Anthera and certain of its officers and/or directors ... Act of 1934. ...
(Date:1/17/2017)...  In a letter to President-elect Donald J. ... outlines AARP,s priorities for Americans age 50 and older ... affordable health care coverage, and lowering the cost of ... to President-elect Trump that "Our nearly 38 million members ... to protect their Medicare and Social Security benefits, protect ...
Breaking Medicine Technology: